{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T17:38:19Z","timestamp":1783705099464,"version":"3.55.0"},"reference-count":5,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,6,8]],"date-time":"2018-06-08T00:00:00Z","timestamp":1528416000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"French Ministery of Health","award":["2009-013482-26"],"award-info":[{"award-number":["2009-013482-26"]}]},{"name":"Direction de la recherche clinique et de l'Innovation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s13075-018-1628-6","type":"journal-article","created":{"date-parts":[[2018,6,8]],"date-time":"2018-06-08T13:10:20Z","timestamp":1528463420000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Serum IL-33 level is associated with auto-antibodies but not with clinical response to biologic agents in rheumatoid arthritis"],"prefix":"10.1186","volume":"20","author":[{"given":"Elodie","family":"Rivi\u00e8re","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00e9mie","family":"Sellam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliette","family":"Pascaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Ravaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques-Eric","family":"Gottenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Mariette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,6,8]]},"reference":[{"issue":"8","key":"1628_CR1","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1002\/art.38671","volume":"66","author":"J Sellam","year":"2014","unstructured":"Sellam J, Marion-Thore S, Dumont F, Jacques S, Garchon H-J, Rouanet S, et al. Use of whole-blood transcriptomic profiling to highlight several pathophysiologic pathways associated with response to rituximab in patients with rheumatoid arthritis: data from a randomized, controlled, open-label trial. Arthritis Rheumatol. 2014;66(8):2015\u201325.","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"1628_CR2","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1186\/s13075-016-1190-z","volume":"18","author":"J Sellam","year":"2016","unstructured":"Sellam J, Rivi\u00e8re E, Courties A, Rouzaire P-O, Tolusso B, Vital EM, et al. Serum IL-33, a new marker predicting response to rituximab in rheumatoid arthritis. Arthritis Res Ther. 2016;18(1):294.","journal-title":"Arthritis Res Ther"},{"issue":"11","key":"1628_CR3","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1001\/jama.2016.13512","volume":"316","author":"J-E Gottenberg","year":"2016","unstructured":"Gottenberg J-E, Brocq O, Perdriger A, Lassoued S, Berthelot J-M, Wendling D, et al. Non-TNF-targeted biologic vs a second anti-TNF drug to treat rheumatoid arthritis in patients with insufficient response to a first anti-TNF drug: a randomized clinical trial. JAMA. 2016;316(11):1172\u201380.","journal-title":"JAMA"},{"issue":"3","key":"1628_CR4","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1136\/annrheumdis-2015-208557","volume":"75","author":"E Rivi\u00e8re","year":"2016","unstructured":"Rivi\u00e8re E, Ly B, Boudaoud S, Chavez H, Nocturne G, Chanson P, et al. Pitfalls for detecting interleukin-33 by ELISA in the serum of patients with primary Sj\u00f6gren syndrome: comparison of different kits. Ann Rheum Dis. 2016;75(3):633\u20135.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"1628_CR5","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1002\/art.30233","volume":"63","author":"J Sellam","year":"2011","unstructured":"Sellam J, Hendel-Chavez H, Rouanet S, Abbed K, Combe B, Le Lo\u00ebt X, et al. B cell activation biomarkers as predictive factors for the response to rituximab in rheumatoid arthritis: a six-month, national, multicenter, open-label study. Arthritis Rheum. 2011;63(4):933\u20138.","journal-title":"Arthritis Rheum"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-018-1628-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13075-018-1628-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-018-1628-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,7]],"date-time":"2019-06-07T23:17:08Z","timestamp":1559949428000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-018-1628-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,8]]},"references-count":5,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["1628"],"URL":"https:\/\/doi.org\/10.1186\/s13075-018-1628-6","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,8]]},"assertion":[{"value":"8 June 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The trial (Clinicaltrials.gov identifier NCT01000441) was approved by the institutional review board of the Comit\u00e9 de Protection des Personnes-Est 1, Strasbourg, France. The study was conducted according to the current regulations of the International Conference on Harmonization guidelines and the principles of the Declaration of Helsinki. All patients gave written informed consent after receiving oral and written information about the trial.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"We confirm that all authors approved the manuscript for submission.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Dr. Rivi\u00e8re reported receiving a PhD grant from Fondation Arhtirits Courtin.Dr. Sellam reported receiving grant support from Roche, Bristol-Myers Squibb, and Pfizer and personal fees from Roche, Pfizer, Abbvie, Bristol-Myers Squibb, Merck Sharp and Dohme, UCB, Janssen, Sandoz, and Novartis.Dr. Gottenberg reported receiving grant support from Abbvie, Pfizer, and Roche and personal fees from Bristol-Myers Squibb, Merck, Sharp, and Dohme, UCB, GlaxoSmithKline, and Novartis.Dr. Mariette reported receiving personal fees from Pfizer, UCB, Bristol-Myers Squibb, and GlaxoSmithKline and grant support from Roche, Pfizer, Bristol-Myers Squibb, GlaxoSmithKline, and Biogen.No other disclosures were reported.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"122"}}